In vitro activity of gepotidacin against urinary tract infection isolates of Enterobacterales, Enterococcus faecalis , and Staphylococcus saprophyticus
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00296-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Meredith A Hackel und 4 weiteren Autor:innen. Beteiligte Einrichtung: IHMA, Schaumburg, Illinois, USA. Hauptthemen laut MEDLINE: Acenaphthenes, Anti-Bacterial Agents, Enterobacteriaceae, Enterococcus faecalis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication through a distinct binding site and unique mechanism of action, providing well-balanced inhibition of two different type II topoisomerase enzymes for most uropathogens. Phase III clinical trials, NCT04020341 (EAGLE-2) and NCT04187144 (EAGLE-3), showed gepotidacin to be non-inferior and superior, respectively, to nitrofurantoin for the treatment of patients with uncomplicated urinary tract infections (uUTIs). To better define gepotidacin in vitro activity against pathogens that commonly cause UTIs, CLSI broth microdilution MICs were determined for gepotidacin and seven comparator agents, and agar dilution MICs were determined for fosfomycin, against 4,000 predominantly UTI isolates of Enterobacterales (3,250), Enterococcus faecalis (500), and Staphylococcus saprophyticus (250) collected globally from 2012 to 2020. Gepotidacin MIC 90 s against the Enterobacterales species tested were 4 µg/mL for Escherichia coli (1,000) and Klebsiella oxytoca (250), 8 µg/mL for Citrobacter spp. (250) and Klebsiella aerogenes (250), 16 µg/mL for Proteus mirabilis (250) and Providencia rettgeri (250), and 32 µg/mL for Enterobacter cloacae (500) and Klebsiella pneumoniae (500). Against the gram-positive species, gepotidacin MIC 90 s were 0.12 µg/mL and 4 µg/mL for S. saprophyticus (250) and E. faecalis (500), respectively. Gepotidacin MIC 90 s for ciprofloxacin not susceptible isolates ranged from 4 µg/mL for E. coli (352) to 128 µg/mL for P. rettgeri (48). Gepotidacin MIC 90 s for presumptive extended spectrum beta-laactamase (ESBL)-positive E. coli (228) and K. pneumoniae (145) were 8 µg/mL and 32 µg/mL, respectively. Gepotidacin was bactericidal (minimum bactericidal concentration [MBC]/MIC ratio ≤4) against 94% (47/50) of isolates tested.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IHMA, Schaumburg, Illinois, USA.
- Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
- GSK, Collegeville, Pennsylvania, USA.
ORCID-Profile: Meredith A Hackel, Nicole E Scangarella-Oman
Zitieren
APA
Hackel, M. A., Karlowsky, J. A., Sahm, D. F., West, J. M., & Scangarella-Oman, N. E. (2025). In vitro activity of gepotidacin against urinary tract infection isolates of Enterobacterales, Enterococcus faecalis , and Staphylococcus saprophyticus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00296-25
Vancouver
Hackel MA, Karlowsky JA, Sahm DF, West JM, Scangarella-Oman NE. In vitro activity of gepotidacin against urinary tract infection isolates of Enterobacterales, Enterococcus faecalis , and Staphylococcus saprophyticus. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00296-25
BibTeX
@article{Hackel2025,
author = {Hackel, Meredith A and Karlowsky, James A and Sahm, Daniel F and West, Joshua M and Scangarella-Oman, Nicole E},
title = {In vitro activity of gepotidacin against urinary tract infection isolates of Enterobacterales, Enterococcus faecalis , and Staphylococcus saprophyticus},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00296-25}
}
EUVIMED